Late-stage trials suggest Lilly’s tirzepatide, sold under Mounjaro, could be a more effective obesity drug that Ozempic or Wegovy, and the company expects a regulatory decision by the end of the year.
Eli Lilly Pushes For Fast-Track Approval Of Mounjaro As Weight-Loss Drug
